tirzepatide difference from semaglutide and key differences, weight loss results (2026) tirzepatide injection dosage chart vs

1 REIMAGINE 2 was a 68-week phase 3 trial evaluating the safety and efficacy of CagriSema in doses 2.4 mg/2.4 mg and 1 mg/1 mg once weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and dose-matched placebo in 2,713 adults with T2D inadequately controlled with metformin with or without an SGLT2 inhibitor

Indeed, a meta-analysis suggested that GLP-1 agonists may improve weight loss and insulin resistance in obese/overweight women than metformin does (234)

Concluding Thoughts Zepbound stands out as a dual receptor agonist affecting both GLP-1 and GIP receptors, expanding its impact beyond traditional GLP-1 medications

Third-party laboratory testing provides independent confirmation of compound identity and purity

Always consult a licensed healthcare provider before starting, stopping, or changing any medication or treatment plan.